【中邮医药】Overseas CXO Performance Flash - IQVIA

English summary

IQVIA reported 26Q2 results, up +10.59% in pre-market trading so far. In 2026Q2, IQVIA achieved revenue of USD 4.368 billion, up 8.7% YoY (8.5% on a constant currency basis), and GAAP net profit attributable to shareholders of USD 256 million, down 3.8% YoY. Revenue from R&D Solutions was USD 2.575 billion, up 8.8% YoY (8.6% on a constant currency basis). Net new orders in the quarter reached USD 3.15 billion, up 19% YoY, with a book-to-bill ratio of 1.22x, a significant improvement from last quarter's USD 2.4 billion and 1.04x. In terms of order growth, R&D Solutions ...; at quarter end, backlog orders were USD 34.2 billion, and net new orders over the trailing twelve months (TTM) reached USD 11.3 billion (up 13% YoY), of which approximately USD 9.2 billion is expected to convert to revenue in the next 12 months (up 7.5% YoY). ...